Tandem Diabetes Care has announced that its t:slim X2 insulin pump with Control-IQ+ automated insulin delivery (AID) technology now integrates with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor. The integration, currently part of an early access program in the U.S., is expected to expand broadly in the second half of 2025. Headquartered in San Diego, Tandem develops and markets advanced insulin delivery systems designed to ease diabetes management. The FreeStyle Libre 3 Plus sensor provides 15-day wear with real-time glucose updates every minute, which are transmitted directly to the insulin pump and viewable on the Tandem mobile app. The Control-IQ+ system makes automated insulin adjustments every five minutes and includes AutoBolus, a feature that calculates and delivers correction doses for missed meals.
Dr. Jordan Pinsker, Chief Medical Officer of Tandem Diabetes Care, expressed, diabetes care should be personalized and noted that the new integration would help more users access Control-IQ+ technology, supporting ADA guidelines for automated insulin delivery. The company plans to bring this combined functionality to international markets later this year. “This is an exciting first step in our strategy to connect Tandem's portfolio of insulin pumps to Abbott’s FreeStyle Libre 3 Plus sensors worldwide. We look forward to expanding access to our t:slim X2 users outside of the U.S. beginning later this year,” added John Sheridan, President and CEO of Tandem.
